research Biological therapy in the treatment of melanoma
Biological therapy boosts the immune system to effectively fight melanoma.
Search
for
Sort by
Research
150-180 / 1000+ results
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research 880 Triptolide (TRP), a diterpenoid, shows a strong efficacy and a safe profile in the topical treatment of actinic keratosis lesions in a UV-B-induced mouse model
Triptolide effectively and safely reduces actinic keratosis lesions in mice.
research 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예
Bortezomib chemotherapy can cause temporary skin rashes.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Treatment of Lipodystrophy with Troglitazone
Troglitazone increases subcutaneous fat in lipodystrophy patients.
research High Response Rate to Bexxar in Advanced Stage Prior Treatment-Resistant Follicular Lymphoma
Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
research Hair repigmentation associated with the use of brentuximab
Brentuximab may cause hair to regain color.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Pustular Eruption in a Patient Treated With Trametinib
Trametinib can cause skin issues, but they can often be managed without stopping the drug.
research Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Dormant tumor cells in ret transgenic mouse melanoma model and their interaction with memory T cells
Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
research A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
research Docetaxel and permanent alopecia
Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
research Cutaneous lupus erythematosus induced by tislelizumab
Tislelizumab can cause cutaneous lupus erythematosus.
research Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
CT-707 is effective and safe for treating certain Chinese lung cancer patients.
research 증례 : Gefitinib에 의해 유발된 반흔성 탈모증
Gefitinib can cause rare scarring hair loss.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Ectopic Expression of a Truncated Isoform of Hair Keratin 81 in Breast Cancer Alters Biophysical Characteristics to Promote Metastatic Propensity
A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.
research Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
research Hypertrichosis of the pinnae in a patient using panitumumab
Panitumumab can cause excessive ear hair growth.